Ms M is an 83-year-old, nulliparous woman who lives in her own home with a friend of 50 years' duration. She presented to Dr D on August 2, 1999, with a list of concerns, one of which was a new set of skin lesions on her abdomen. Dr D immediately suspected metastatic cancer and scheduled a fine needle aspiration for that day. The pathological finding was an unusual lipoma.
THE SCIENCE OF PROGNOSIS
Although physicians tend to overestimate substantially the survival of patients with advanced cancer receiving palliative care, [1] [2] [3] [4] [5] [6] in this vignette, Dr D substantially underestimated Ms M's survival, an event which has been shown to occur in less than 20% of patients. 7 
What Is the Diagnosis?
Since the science of prognosis is anchored in disease diagnosis and extent, Ms M's diagnostic ambiguity contributed to making this case extremely challenging prognostically. Her initial skin lesions had a clinical history and course apparently consistent with malignancy but had an atypical appearance on pathological examination. Pathological evaluation of the narrowed colon had the appearance of a metastasis from a gastric primary malignancy with a singlecell infiltrative pattern, but there was no clinical evidence of a gastric primary source. Finally, the patient's apparent disseminated gastric cancer responded dramatically to tamoxifen, a therapy that has not proved effective in clinical trials of estrogen receptor-positive gastric cancers. 7 Another explanation for the patient's findings and course is that she may have had a different type of disseminated cancer. Lobular breast cancer is also an adenocarcinoma that expresses estrogen receptors, has a single-cell infiltrative appearance, can seed the peritoneum and infiltrate organs, and can be associated with clinically and radiographically silent primary tumors. Either way, she had a disseminated solid tumor, prompting the question whether determining the primary tumor site (eg, further diagnostic evaluations or referral to an oncologist) would change the clinical management of the patient. The answer is yes, sometimes.
Ms M is an example of the potential heterogeneity of advanced solid tumors, both with respect to prognosis and available therapies. Her case reminds us that not all solid tumors are the same. Using the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) statistical software SEER*Stat program on 9 registry public-use data sets ), 8 we found that disseminated gastric cancer and disseminated breast cancer have very different survival curves, with the median survival from metastatic gastric cancer only 4.1 months and the median survival from metastatic breast cancer nearly 5 times as long at 18.5 months. There is also great prognostic variability between these disseminated cancers, with dramatically different interquartile ranges (IQRs): gastric 1.5 to 8.5 months vs breast 5.5 to 43.5 months. Part of the difference relates to tumor biology, but part, too, likely relates to the effective and well-tolerated therapeutic option for disseminated breast cancer (ie, hormonal therapy), which has no parallel in disseminated gastric cancer.
What Are the Goals of Treatment?
In addition to helping to predict prognosis directly, determining diagnosis informs treatment, which may also modify prognosis. Despite the significant ambiguity about her diagnosis from the time of presentation until death, Dr D provided Ms M with outstanding care by prescribing tamoxifen, which likely exceeded her initial therapeutic goal of palliation (ie, reducing or containing her visceral metastases to decrease likelihood of recurrent bowel obstructions) and ended up also providing her with life prolongation. Ideally, a consulting oncologist would have explicitly considered how different therapies given to palliate the patient's bowel obstruction might affect survival. For instance, such a consulting physician might first consider the average survival of all women with metastatic breast cancer as 18.5 months (SEER value includes both patients treated with anticancer therapy and those untreated). Then, they could estimate how either a clinical response to tamoxifen with tumor shrinkage or stabilization vs tumor progression might modify these averages. In this scenario, the physician might consider that, on average, similar women treated as part of the original clinical trials of tamoxifen lived approximately 24 months, with an IQR of 18 months to more than 5 years. [9] [10] [11] Those patients who experience tumor shrinkage or stabilization with tamoxifen would likely fall on the longer end of the survival distribution and those patients whose tumors progressed while taking tamoxifen would tend to fall on the shorter end of the survival distribution. Thus, the consultation with an oncologist might have yielded a longer point estimate of survival (ie, 24 months) and a greater distribution of survival, 18 months to more than 5 years, depending on the response to tamoxifen and to subsequent therapies (eg, aromatase inhibitors, chemotherapy).
Prognostic Consultation
In a patient such as Ms M, with an incompletely defined illness, it is reasonable to ask, "Will further investigation change clinical management?" With respect to disseminated malignancies in frail elderly patients who might not tolerate aggressive chemotherapies, some internists might recommend against aggressive diagnostic evaluations (sometimes foregoing consultation with an oncologist) and instead recom-mend initiating supportive care. Ms M is an example of why aggressive evaluations by subspecialists may be of value for some patients: (1) to enhance prognostic certainty through more refined characterization of the disease, and (2) to inform supportive care. For this patient, a more complete definition of her illness (ie, determining the primary tumor site) may have changed both what the physician told the patient about her expected survival and how the physician managed the patient's supportive care (eg, considering that tamoxifen might prolong survival, timing of a referral to hospice, identifying the types of palliative therapies).
Quite apart from the issue of greater prognostic accuracy through refinement of diagnosis and familiarity with the survival implications of possible therapies, consulting physicians (eg, oncologists, palliative medicine specialists, and others) may have enhanced prognostic accuracy relative to the referring physician by virtue of the fact that they have no prior relationship with the patient. This recommendation stems from research suggesting that physicians with less emotional attachment to patients may provide more realistic estimates of their survival 6 and that prognoses averaged across several physicians are more accurate than the prognosis of a single physician. 12, 13 The success of this technique may relate to minimizing the importance of extreme estimates from physicians (ie, decreasing the signal-tonoise ratio), which may themselves relate to the level of physician emotional attachment to the patient. Thus, through either formal (eg, oncologic consultation, tumor boards) or informal consultation (eg, curbside consultations), physicians may find disinterested colleagues helpful in improving the accuracy of the prognostic estimates they formulate regarding their patients, and patients may wish to seek such second opinions themselves.
Other Sources of Prognostic Information
Unfortunately, there is no single, simple source of prognostic information, and finding it can often be a challenge for physicians. 14, 15 However, physicians may find relevant prognostic information in previously published survival curves, in medical literature examining the survival implications of patient attributes, and in their own clinical predictions about patient survival.
Survival Curves
The SEER stage-specific survival curves are available in staging manuals, 16 oncologic textbooks, 17 and publicly available data, 18 and survival curves are routinely generated from clinical trials of anticancer therapy. Other sources of survival data are natural history studies and randomized therapy trials that include a treatment arm that consists of supportive care only and not anticancer therapy. Typically, natural history studies are single-institution case series of untreated patients with mortality follow-up and have been reported in a variety of cancers, including head and neck cancer, 19 breast cancer, 20 and hepatocellular cancer. 21 Randomized clinical trials with a "best supportive care" arm include trials in advanced non-small cell lung cancer, [22] [23] [24] [25] hepatocellular cancer, 26 metastatic colon cancer, 27 5-fluorouracil refractory stage IV colon cancer, 28 stage IV pancreatic cancer, 29 and stage IV gastric cancer.
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Performance Status
Performance status is a global measure of a patient's functional capacity and has substantial prognostic significance. Consistently, it has been found to predict survival in cancer patients 31 and it is frequently used as a selection factor for patients entering clinical trials and also as an adjustment factor in the subsequent analyses of treatment effect. Several different metrics have been developed to determine performance status. The Karnofsky performance status score is used most often. It ranges from 100%, signifying normal functional status with no complaints or evidence of disease, to 0, signifying death.
Multiple studies 2, 5, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] report that cancer patients with poorer performance status have shorter survival. Several studies report that among patients enrolled in palliative care programs, a Karnofsky performance status score of less than 50% (substantial disability) suggests a life expectancy of less than 8 weeks. 2, 5, 33, 35, 46, 47 
Patient Signs and Symptoms
Clinical signs and symptoms have long been used as potential indicators of patient survival in advanced cancer. In 1966, Feinstein and others first outlined the utility of such indicators, even in preference to biological details of a patient's condition. 48 
Physicians' Clinical Predictions
Many previous studies of prognostic accuracy for groups of patients enrolled in palliative care programs show that physicians tend to overestimate patient survival by a factor of 3 to 5. [1] [2] [3] [4] [5] [6] Nonetheless, these estimates do correlate with patients' actual survival. 5, 6, 50 This fact suggests that physicians have potentially valuable discriminatory abilities, which may be a useful source of information regarding patient survival. 58 Thus, integration of clinical predictions with other known prognostic factors may be beneficial in estimating patient survival.
Integrated Models
Investigators have sought to predict patient survival more accurately by combining many of these previously identified clinical predictors. The most recent iteration of studies report integrated models that render a single prognostic score from a combination of prognostic variables. formance status and specific clinical signs and symptoms termed the Palliative Prognostic Index. The investigators report that the index predicted 3-week survival with a sensitivity of 83% and a specificity of 85%, and 6-week survival with a sensitivity of 79% and a specificity of 77%. This model was developed in one sample of patients enrolled in palliative care and validated in a second sample. Further research is needed to determine whether these scoring systems are useful in the clinical care of cancer patients and whether they are applicable to patients who are not yet enrolled in palliative care programs. With respect to the clinical utility of the scoring systems, treating physicians will need to determine if the test characteristics of the tools (eg, sensitivity and specificity) fall above certain minimum thresholds for use in clinical decisions. Because of the issue of "zerotime" (ie, the analytic impact of the selection of the time at which measurement of survival begins), 48, 49 many of the algorithms that rely on the Karnofsky performance status score, symptoms, or laboratory values obtained after referral to hospice may not be applicable to patients with advanced cancer prior to referral to hospice.
THE ART OF PROGNOSTIC DISCLOSURE
Disclosing a poor prognosis to patients is among a physician's most difficult tasks. 12, 59, 60 Physicians must understand how critically important it is for patients to obtain information about the expected course of their illness (including their expected survival). As Ms M articulates, patients use this information in a variety of ways, including as a way to inform decisions about which medical therapies to pursue [61] [62] [63] [64] [65] [66] and when to put their personal affairs in order. Patients with terminal illness want their physicians to be honest about the severity of their illness, but also want physicians to be optimistic. [64] [65] [66] It may be the difficulty of meeting both these seemingly disparate needs that leads some physicians to choose to communicate overly optimistic survival estimates to patients 67 and thus contribute to the documented discrepancies between patients and their physicians on the matter of prognosis.
68,69
An Algorithm for Disclosure
Communicating bad news about a poor prognosis can be made easier with the use of algorithms that are created to include those elements that patients say they want and need to make decisions about how they will spend their remaining time. [61] [62] [63] [64] [65] [66] Several groups have outlined approaches to the successful disclosure of bad news. [70] [71] [72] [73] [74] In one approach, the physician understands the encounter to include 4 temporally ordered segments, each with its own, important communication tasks. 73 Roughly paraphrased, these segments are the preparation, the content, the patient's response, and the close. The TABLE contains a summary of the types of tasks that, based on prior research of patients' information preferences in advanced cancer, [64] [65] [66] we and other clinicians [70] [71] [72] [73] [74] believe are important components of each segment. As Dr D clearly appreciated, and Ms M recognized as crucial, in the preliminary phase of prognostic disclosure, the physician prepares for the conversation with the patient by undertaking extensive research regarding the patient's illness, expected survival, and therapeutic considerations, and ideally sets the scene to be as supportive as possible for the patient and family. Arrangements should be made for an inperson conversation without interruptions and with ample time for questions. Research suggests that cancer patients place the greatest importance on their physician being upto-date on research of the patient's particular type of cancer. They also rated highly the importance of physicians giving patients their full attention and patients having enough time to have asked and have answered all their questions. 64 As is evident in the preceding passage, Dr D appreciated that such discussions between patients and their physicians are nodal points in patients' lives and deserve special focus and steadfast emotional support.
The Content
DR D: I said that the disease was far advanced and I expected that her life would be limited and I believed it was on the order of months, to give her a ballpark [figure]. It was late summer when this was diagnosed and I really didn't think that she would live until Christmas, realistically.
In this phase of prognostic disclosure, the physician discusses the patient's illness and expected prognosis. In the case of Ms M, Dr D might have discussed the ambiguity of Ms M's diagnosis and the other possibilities on the differential diagnosis list. A way to engage prognosis when the diagnosis is uncertain is to discuss survival estimates of each of the diagnoses being considered. We advocate that when communicating prognosis to patients, the physician should first anchor the estimate in an average survival for similar patients, disclosing the median survival and IQR. Then they can comment on how the patient's existing performance status, symptoms, and subsequent treatment response might modify the estimate. For example, in this situation the physician might have acknowledged to the patient that her diagnosis was unclear and thus her prognosis was unclear. She could explain that the diagnoses she was considering were stage IV gastric cancer and stage IV breast cancer and that each had very different survival horizons and likely responses to therapy. If the patient was one who appreciated greater detail, she could explain that of 100 patients with stage IV gastric cancer, the average survival is 16 at Massachusetts General Hospital on June 2, 2011 jama.ama-assn.org Downloaded from weeks and 25% living 34 weeks or longer. 8 She could then provide the same parameters for stage IV breast cancer. Although physicians report that they have mixed feelings about using survival estimates and statistics in their discussions with patients about poor prognoses, 12 the technique has the clear advantage of anchoring patients in a prognostic estimate that is reasonable. With further discussion of the IQR, patients may come to understand the prognostic range and can plan accordingly.
Articulating explicitly the goals of treatment and whether the treatment has the potential of prolonging life is also critical. Dr D might have told Ms M that since it was possible that her tumor originated in the breast, it might be worth trying effective treatment for breast cancer to shrink or stabilize the tumor to prevent another bowel obstruction. If the treatment worked, which could be assessed by following the size of the skin tumors, then the bowel problems might improve, and Ms M might live longer than the aver-
Table. Four Elements of an Approach to Delivering a Prognosis
Tasks Possible Ways to Express It Preparation
Research the patient's condition to determine prognostic parameters with and without therapy, both "life-prolonging" and "palliative"
Arrange meeting in private place with ample time, seating, tissues, and no interruptions (eg, telephones, pagers, staff) Alert the patient ahead of time that you need to discuss important aspects of his or her health. Suggest that the patient bring a person important in his or her life to the meeting "The next time we meet, we will be reviewing important test results regarding your illness. I think it is important that you bring with you someone who is important to you." At the meeting, first establish how the patient is feeling, identifying symptoms that can be the later focus of discussion of palliative therapies. Establish current level of debilitation (ie, performance status) State the news clearly, simply, and sensitively "It appears that the cancer has spread to your bones, which means that it is no longer curable."
Provide information in small amounts at a time Make optimistic statements that are truthful "I am very hopeful that with medicine we can control your bone pain."
Anchor the survival estimate you communicate in previously published data and modify it by the patient's current clinical status "On average, patients with stage IV gastric cancer live 4 months. One quarter of patients will live 1.5 months or less and one quarter live 8 months or more. While I do not know for sure where you are in that group, the fact that you are feeling so poorly right now and in bed most of the time makes me concerned that you may not live longer than the average 4 months."
Patient's Response
Acknowledge the patient's affect and express empathy "I can tell how very difficult it is for you to hear this bad news." Assure the patient of your continued involvement in his or her medical care. Squarely address the issue that forgoing chemotherapy does not create a therapeutic void; patients often conflate "doing something" with chemotherapy "Although we cannot cure or shrink your cancer with chemotherapy, we certainly can continue to take care of you and treat you with medicines for any symptoms that the cancer may cause. There is always something that we can do to help you."
Close
Summarize the new news sensitively and outline a short-term plan of care "What we have discussed is that your cancer has progressed to involve your bones, which has caused the calcium in your blood to become dangerously high. What I recommend we do next is to focus on returning the calcium level to normal and strengthening the bone around the tumor by adding a new medicine that is given by vein every month. I recommend that you get the first dose today in our office." Arrange a follow-up visit (even if the patient is being referred for hospice care), since it is a tangible example of your continued commitment to the patient Offer to discuss the news with people important to the patient who are not present In this phase, the physician carefully observes the patient and acknowledges the patient's affect and response after hearing the probable effects of the illness and the patient's expected survival. The patient may identify concerns to which the physician can respond to help the patient better understand the illness and how it can be managed. Making optimistic but true statements may help the patient focus on tenable goals of therapy. In the final phase of prognostic disclosure, the physician summarizes the information discussed, makes a short-term plan with the patient, and as Dr D clearly conveyed, assures the patient and her support circle of the physician's continued involvement and availability. As a substantive matter, in this case, the physician might review that the patient has a tumor adherent to the bowel causing a blockage, that although its origin is not clear, it is most likely gastric cancer or breast cancer. Since these cancers have different survival patterns and different therapies, the physician explains how she and the patient will need to revisit the issue of diagnosis, treatment, and survival as they learn more about how the tumor responds to the recommended tamoxifen therapy. They make a plan to start the tamoxifen, to evaluate the size of the skin lesions on a certain date, and to revisit diagnosis, prognosis, and treatment at that time. We believe that such concrete plans, even in the therapeutic situation of purely supportive care with opioids or antipyretics, have the dual effects of focusing on improving the patient's condition and assuaging patients' fears that "nothing more can be done," and thus they will be abandoned by their physician. As described by Dr D, physicians may have the opportunity to improve their patients' end-of-life experiences by simply helping them to understand the life-limiting nature of their illness and defining their expected survival. As illustrated by the case of Ms M, patients often want to accomplish certain things before dying, and comprehending that remaining time is short may prompt them to do those things. Such efforts should be regarded as at least as important as the fundamental therapeutic tasks of pain and symptom management and may well be as professionally rewarding. Thus, prognosis deserves prominence in the care of patients with life-threatening diseases like advanced cancer, and continued research on the science of prognosis and the art of its disclosure is needed. 
CONCLUSIONS
